PAUSHAKLTD
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
India launches anti-dumping probe into ethyl chloroformate imports from China
By Manoj Kumar
NEW DELHI, March 18 (Reuters) - India on Tuesday opened an anti-dumping investigation into ethyl chloroformate imports from China after a domestic producer alleged the chemical used in pharmaceutical and agrochemical manufacturing was being sold at unfairly low prices.
The Directorate General of Trade Remedies (DGTR), under the federal trade ministry, said it initiated the probe following an application by Paushak PAUS.NS that alleged that imports from China had caused "material injury" to domestic producers.
The Chinese embassy in New Delhi did not immediately respond to a request for comment.
In December, India imposed a three-year import tariff of 11% to 13% on some steel imports, in an effort to curb cheap Chinese products.
Ethyl chloroformate is an organic chemical intermediate widely used in pharmaceutical and agrochemical manufacturing.
The probe could lead to import duties, higher costs for drugmakers and agrochemical firms while shielding local producers if dumping is confirmed, trade analysts said.
In a statement, the DGTR said it would examine whether the product was being dumped on the Indian market and whether anti-dumping duties were warranted to offset the alleged injury to domestic producers.
In its filing, Paushak said it is India's sole domestic producer of ethyl chloroformate and it is responsible for the country's entire output. It alleged that rising imports from China had led to price suppression and weakened profitability.
The DGTR said its preliminary assessment indicated the dumping margin appeared to be above the de minimis level, suggesting significant price undercutting by Chinese exporters.
The investigation will cover the period from October 2024 to September 2025, the DGTR said, and will assess evidence from exporters, importers and other interested parties before deciding whether to recommend duties to the government.
In a separate case, the DGTR also initiated an anti-dumping investigation into imports of hexamine - another intermediate used by the chemical and pharmaceutical industries - originating in or exported from China, Russia and the United Arab Emirates.
(Reporting by Manoj Kumar; Editing by Thomas Derpinghaus)
((manoj.kumar@thomsonreuters.com; +919810286200; Twitter:@manojgulnar;))
By Manoj Kumar
NEW DELHI, March 18 (Reuters) - India on Tuesday opened an anti-dumping investigation into ethyl chloroformate imports from China after a domestic producer alleged the chemical used in pharmaceutical and agrochemical manufacturing was being sold at unfairly low prices.
The Directorate General of Trade Remedies (DGTR), under the federal trade ministry, said it initiated the probe following an application by Paushak PAUS.NS that alleged that imports from China had caused "material injury" to domestic producers.
The Chinese embassy in New Delhi did not immediately respond to a request for comment.
In December, India imposed a three-year import tariff of 11% to 13% on some steel imports, in an effort to curb cheap Chinese products.
Ethyl chloroformate is an organic chemical intermediate widely used in pharmaceutical and agrochemical manufacturing.
The probe could lead to import duties, higher costs for drugmakers and agrochemical firms while shielding local producers if dumping is confirmed, trade analysts said.
In a statement, the DGTR said it would examine whether the product was being dumped on the Indian market and whether anti-dumping duties were warranted to offset the alleged injury to domestic producers.
In its filing, Paushak said it is India's sole domestic producer of ethyl chloroformate and it is responsible for the country's entire output. It alleged that rising imports from China had led to price suppression and weakened profitability.
The DGTR said its preliminary assessment indicated the dumping margin appeared to be above the de minimis level, suggesting significant price undercutting by Chinese exporters.
The investigation will cover the period from October 2024 to September 2025, the DGTR said, and will assess evidence from exporters, importers and other interested parties before deciding whether to recommend duties to the government.
In a separate case, the DGTR also initiated an anti-dumping investigation into imports of hexamine - another intermediate used by the chemical and pharmaceutical industries - originating in or exported from China, Russia and the United Arab Emirates.
(Reporting by Manoj Kumar; Editing by Thomas Derpinghaus)
((manoj.kumar@thomsonreuters.com; +919810286200; Twitter:@manojgulnar;))
Paushak Company Initiates Commissioning Of New Multi-Purpose Plant
Jan 21 (Reuters) - Paushak Ltd PAUS.NS:
COMPANY INITIATES COMMISSIONING OF NEW MULTI-PURPOSE PLANT
INVESTMENT ABOUT 1.75 BILLION RUPEES
Source text: ID:nNSEc6l8cN
Further company coverage: PAUS.NS
Jan 21 (Reuters) - Paushak Ltd PAUS.NS:
COMPANY INITIATES COMMISSIONING OF NEW MULTI-PURPOSE PLANT
INVESTMENT ABOUT 1.75 BILLION RUPEES
Source text: ID:nNSEc6l8cN
Further company coverage: PAUS.NS
Paushak Issues Bonus Shares
Aug 11 (Reuters) - Paushak Ltd PAUS.BO:
ISSUE BONUS SHARES IN 3:1 RATIO
Source text: ID:nBSE6j1f5
Further company coverage: PAUS.BO
Aug 11 (Reuters) - Paushak Ltd PAUS.BO:
ISSUE BONUS SHARES IN 3:1 RATIO
Source text: ID:nBSE6j1f5
Further company coverage: PAUS.BO
Paushak Says Abhijit Joshi Resigns As CEO
April 2 (Reuters) - Paushak Ltd PAUS.BO:
PAUSHAK - ABHIJIT JOSHI RESIGNS AS CEO
Source text: ID:nBSE4YKy1t
Further company coverage: PAUS.BO
April 2 (Reuters) - Paushak Ltd PAUS.BO:
PAUSHAK - ABHIJIT JOSHI RESIGNS AS CEO
Source text: ID:nBSE4YKy1t
Further company coverage: PAUS.BO
Rbm Infracon Gets Order Worth 5.9 Million Rupees From Paushak
Dec 10 (Reuters) - Paushak Ltd PAUS.BO:
GETS ORDER WORTH 5.9 MILLION RUPEES FROM PAUSHAK
Source text: ID:nNSEyc3HQ
Further company coverage: PAUS.BO
Dec 10 (Reuters) - Paushak Ltd PAUS.BO:
GETS ORDER WORTH 5.9 MILLION RUPEES FROM PAUSHAK
Source text: ID:nNSEyc3HQ
Further company coverage: PAUS.BO
Paushak Says Annual Maintenance Of Plants And Utilities Has Been Completed
Dec 6 (Reuters) - Paushak Ltd PAUS.BO:
PAUSHAK LTD - ANNUAL MAINTENANCE OF PLANTS AND UTILITIES HAS BEEN COMPLETED
PAUSHAK LTD - PHASE WISE MANUFACTURING OPERATIONS RESUMED WITH EFFECT FROM DEC 6
Source text: ID:nBSE7Vxg29
Further company coverage: PAUS.BO
Dec 6 (Reuters) - Paushak Ltd PAUS.BO:
PAUSHAK LTD - ANNUAL MAINTENANCE OF PLANTS AND UTILITIES HAS BEEN COMPLETED
PAUSHAK LTD - PHASE WISE MANUFACTURING OPERATIONS RESUMED WITH EFFECT FROM DEC 6
Source text: ID:nBSE7Vxg29
Further company coverage: PAUS.BO
India's Paushak drops on announcing annual maintenance shutdown of facilities
** Specialty chemicals maker Paushak PAUS.BO falls ~4% to 5,290 rupees
** Co will shut its manufacturing facilities for annual maintenance in phases between Nov. 26 and Dec. 6
** PAUS did not disclose the quantified hit to production due to the closure
** YTD, stock down ~13%
(Reporting by Hritam Mukherjee in Bengaluru)
** Specialty chemicals maker Paushak PAUS.BO falls ~4% to 5,290 rupees
** Co will shut its manufacturing facilities for annual maintenance in phases between Nov. 26 and Dec. 6
** PAUS did not disclose the quantified hit to production due to the closure
** YTD, stock down ~13%
(Reporting by Hritam Mukherjee in Bengaluru)
Paushak To Shutdown Manufacturing Facilities From Nov 26 To Dec 6 For Maintenance
Nov 25 (Reuters) - Paushak Ltd PAUS.BO:
PAUSHAK - TO SHUTDOWN MANUFACTURING FACILITIES FROM NOV 26 TO DEC 6 FOR MAINTENANCE
Source text: ID:nBSE43ncXZ
Further company coverage: PAUS.BO
Nov 25 (Reuters) - Paushak Ltd PAUS.BO:
PAUSHAK - TO SHUTDOWN MANUFACTURING FACILITIES FROM NOV 26 TO DEC 6 FOR MAINTENANCE
Source text: ID:nBSE43ncXZ
Further company coverage: PAUS.BO
Paushak To Undertake Manufacturing Facilities Shutdown In Phased Manner
Oct 2 (Reuters) - Paushak Ltd PAUS.BO:
PROPOSING TO UNDERTAKE SHUTDOWN OF ITS VARIOUS MANUFACTURING FACILITIES IN A PHASED MANNER
SHUTDOWN FROM 2ND OCTOBER TO 27TH OCTOBER
Source text for Eikon: ID:nBSE5ZxpV3
Further company coverage: PAUS.BO
Oct 2 (Reuters) - Paushak Ltd PAUS.BO:
PROPOSING TO UNDERTAKE SHUTDOWN OF ITS VARIOUS MANUFACTURING FACILITIES IN A PHASED MANNER
SHUTDOWN FROM 2ND OCTOBER TO 27TH OCTOBER
Source text for Eikon: ID:nBSE5ZxpV3
Further company coverage: PAUS.BO
India's Paushak March-Quarter PAT Rises
May 4 (Reuters) - Paushak Ltd PAUS.BO:
MARCH-QUARTER PAT 143.5 MILLION RUPEES VERSUS 132.2 MILLION RUPEES
MARCH-QUARTER REVENUE FROM OPERATIONS 564.6 MILLION RUPEES VERSUS 526.2 MILLION RUPEES
DIVIDEND 17.50 RUPEES PER SHR
ABHIJIT JOSHI REAPPOINTED CEO
Source text for Eikon: ID:nBSE62FjGw
Further company coverage: PAUS.BO
May 4 (Reuters) - Paushak Ltd PAUS.BO:
MARCH-QUARTER PAT 143.5 MILLION RUPEES VERSUS 132.2 MILLION RUPEES
MARCH-QUARTER REVENUE FROM OPERATIONS 564.6 MILLION RUPEES VERSUS 526.2 MILLION RUPEES
DIVIDEND 17.50 RUPEES PER SHR
ABHIJIT JOSHI REAPPOINTED CEO
Source text for Eikon: ID:nBSE62FjGw
Further company coverage: PAUS.BO
Upcoming Events:
e-Voting
Events:
Bonus
Split
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Paushak do?
Paushak Ltd specializes in manufacturing Phosgene and its derivatives, which are used in various industries such as pharmaceuticals, agrochemicals, polyurethanes, perfumeries, and dyes. Their product range includes Isocyanates, Chloroformates, Carbamoyl Chlorides, Urea, and more.
Who are the competitors of Paushak?
Paushak major competitors are Atul, Hikal, Ultramar & Pigments, Valiant Organics, Chemcon Speciality, 20 Microns, DMCC Speciality Chem. Market Cap of Paushak is ₹992 Crs. While the median market cap of its peers are ₹650 Crs.
Is Paushak financially stable compared to its competitors?
Paushak seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Paushak pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Paushak latest dividend payout ratio is 12.48% and 3yr average dividend payout ratio is 11.27%
How has Paushak allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Paushak balance sheet?
Balance sheet of Paushak is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Paushak improving?
No, profit is decreasing. The profit of Paushak is ₹36.41 Crs for TTM, ₹49.38 Crs for Mar 2025 and ₹54.35 Crs for Mar 2024.
Is the debt of Paushak increasing or decreasing?
Yes, The net debt of Paushak is increasing. Latest net debt of Paushak is ₹59.07 Crs as of Sep-25. This is greater than Mar-25 when it was ₹23.79 Crs.
Is Paushak stock expensive?
Paushak is not expensive. Latest PE of Paushak is 27.25, while 3 year average PE is 45.63. Also latest EV/EBITDA of Paushak is 17.54 while 3yr average is 33.01.
Has the share price of Paushak grown faster than its competition?
Paushak has given lower returns compared to its competitors. Paushak has grown at ~-15.58% over the last 5yrs while peers have grown at a median rate of -0.53%
Is the promoter bullish about Paushak?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Paushak is 67.28% and last quarter promoter holding is 67.28%.
Are mutual funds buying/selling Paushak?
There is Insufficient data to gauge this.
